Table 2.

Systemic treatment received according to insurance status and treatment line.

1st line	No insurance	Social Security	Private insurance	p-value
Sunitinib	44.3%	65.1%	16.7%	<0.001*
Sorafenib	0.5%	14.5%	5.6%
Pazopanib	25.9%	11.5%	55.6%
Interferon (INF)	22.2%	4.1%	0
Bevacizumab/INF	0	3.8%	5.6%
Clinical Trial	1.6%	0.5%	0
Other	5.5%	0.5%	16.5%
2nd line
Sorafenib	18.5%	40.3%	0	<0.001*
Sunitinib	11.1%	16.8%	12.5%
Pazopanib	9.3%	14.8%	50%
Everolimus	11.1%	14.1%	12.5
Bevacizumab/INF	0	8.1%	0
Nivolumab	9.3%	0	25%
Other	40.7%	5.9%	0
3rd line
Nivolumab	33.3%	9.1%	40%	0.025^
Everolimus	0	22.7%	20%
Bevacizumab/INF	0	6.8%	20%
Clinical Trial	0	0	20%
Sorafenib	8.3%	22.7%	0
Pazopanib	33.3%	13.6%	0
Other	25.1%	25.1%	0
4th line
Sunitinib	0	23.7%	50%	0.178^
Nivolumab	0	0	50%
Everolimus	0	18.2%	0
Sorafenib	0	18.2%	0
Axitinib	100%	0	0
Other	0	39.9%	0

*Chi-square test.

^Fisher’s exact test.

Bold values are those that reached statistical significance.